Compare Stocks

→ $25,000 into $109,616 in two months? (From WealthPress) (Ad)

Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS).

Comparative Price Performance Over Time

Compare Stocks - Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
APTX Aptinyx	$0.10 +3.1%	$0.08	$0.01 ▼ $0.72	N/A	1.27	1.32 million shs	231,100 shs
KALV KalVista Pharmaceuticals	$10.35 -7.7%	$12.53	$7.21 ▼ $16.88	$472.93M	0.88	729,681 shs	482,316 shs
LCI Lannett		$1.54	$0.64 ▼ $3.72	$7.38M	0.95	92,067 shs	280,600 shs
TRVN Trevena	$0.38 -2.6%	$0.49	$0.30 ▼ $3.28	$7.11M	1.1	382,182 shs	61,305 shs
XOMA XOMA	$25.64 -1.7%	$24.69	$13.48 ▼ $27.00	$303.56M	0.58	13,626 shs	8,219 shs

20 Stocks to Sell Now

MarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio? Find out by clicking the link below.

Get This Free Report

Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
APTX Aptinyx	0.00%	0.00%	0.00%	0.00%	-20.00%
KALV KalVista Pharmaceuticals	-7.67%	-11.16%	-7.01%	-19.46%	+28.57%
LCI Lannett	0.00%	0.00%	0.00%	0.00%	0.00%
TRVN Trevena	-1.80%	-4.32%	-12.41%	-40.86%	-39.04%
XOMA XOMA	-1.72%	+5.73%	+6.83%	+24.41%	+41.03%

The A.I. story nobody is telling you (Read ASAP) (Ad)

There's been a lot of buzz surrounding A.I. over the past year... Most of it is just hype and speculation. But there's one recent A.I. development you NEED to hear about...

Click here to see Louis' new video for yourself.

MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
APTX Aptinyx	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
KALV KalVista Pharmaceuticals	4.0854 of 5 stars	3.5	1.0	0.0	4.6	3.2	2.5	0.6
LCI Lannett	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
TRVN Trevena	1.7505 of 5 stars	3.5	3.0	0.0	0.0	2.5	0.0	0.6
XOMA XOMA	3.6312 of 5 stars	3.5	2.0	0.0	3.0	2.4	1.7	0.6

Analyst Ratings

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
APTX Aptinyx	N/A	N/A	N/A	N/A
KALV KalVista Pharmaceuticals	3.00	Buy	$26.33	154.43% Upside
LCI Lannett	N/A	N/A	N/A	N/A
TRVN Trevena	3.00	Buy	$9.00	2,262.20% Upside
XOMA XOMA	3.00	Buy	$74.00	188.61% Upside

Current Analyst Ratings

Latest LCI, APTX, XOMA, KALV, and TRVN Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
4/11/2024	KALV KalVista Pharmaceuticals	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$35.00
4/2/2024	TRVN Trevena	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$9.00
2/16/2024	XOMA XOMA	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$74.00
2/14/2024	KALV KalVista Pharmaceuticals	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$16.00 ➝ $24.00
2/13/2024	KALV KalVista Pharmaceuticals	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$22.00 ➝ $35.00

(Data available from 4/25/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
APTX Aptinyx	$1M	N/A	N/A	N/A	$0.57 per share	N/A
KALV KalVista Pharmaceuticals	N/A	N/A	N/A	N/A	$4.71 per share	N/A
LCI Lannett	$340.58M	0.00	N/A	N/A	($23.34) per share	0.00
TRVN Trevena	$3.12M	2.24	N/A	N/A	($0.44) per share	-0.87
XOMA XOMA	$4.76M	62.70	N/A	N/A	$7.72 per share	3.32

Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
APTX Aptinyx	-$64.85M	-$0.98	N/A	N/A	N/A	N/A	N/A	N/A	N/A
KALV KalVista Pharmaceuticals	-$92.91M	-$3.15	N/A	N/A	N/A	N/A	-86.06%	-72.65%	7/5/2024 (Estimated)
LCI Lannett	-$231.62M	-$18.88	N/A	N/A	N/A	-62.40%	N/A	-13.39%	N/A
TRVN Trevena	-$40.29M	-$3.13	N/A	N/A	N/A	N/A	-1,018.15%	-98.93%	5/20/2024 (Estimated)
XOMA XOMA	-$40.83M	-$4.04	N/A	N/A	N/A	-886.91%	-25.17%	-17.08%	5/14/2024 (Estimated)

Latest LCI, APTX, XOMA, KALV, and TRVN Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue	Details
3/11/2024	Q3 2024	KALV KalVista Pharmaceuticals	-$0.75	-$0.84	-$0.09	-$0.84	N/A	N/A
3/8/2024	Q4 2023	XOMA XOMA	-$0.36	-$0.49	-$0.13	$0.89	$1.01 million	$1.83 million

Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
APTX Aptinyx	N/A	N/A	N/A	N/A	N/A
KALV KalVista Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
LCI Lannett	N/A	N/A	N/A	N/A	N/A
TRVN Trevena	N/A	N/A	N/A	N/A	N/A
XOMA XOMA	N/A	N/A	N/A	N/A	N/A

Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
APTX Aptinyx	N/A	N/A	N/A
KALV KalVista Pharmaceuticals	N/A	5.44	5.44
LCI Lannett	N/A	2.23	1.39
TRVN Trevena	8.35	4.66	4.66
XOMA XOMA	1.34	8.68	8.68

Ownership

Institutional Ownership

Company	Institutional Ownership
APTX Aptinyx	N/A
KALV KalVista Pharmaceuticals	N/A
LCI Lannett	40.28%
TRVN Trevena	13.56%
XOMA XOMA	95.92%

Insider Ownership

Company	Insider Ownership
APTX Aptinyx	10.97%
KALV KalVista Pharmaceuticals	12.30%
LCI Lannett	13.12%
TRVN Trevena	2.40%
XOMA XOMA	7.20%

Miscellaneous

Company	Employees	Shares Outstanding	Free Float	Optionable
APTX Aptinyx	12	N/A	N/A	Not Optionable
KALV KalVista Pharmaceuticals	118	42.19 million	37.00 million	Optionable
LCI Lannett	810	10.77 million	9.35 million	Optionable
TRVN Trevena	23	18.32 million	17.88 million	Optionable
XOMA XOMA	13	11.64 million	10.80 million	Optionable

LCI, APTX, XOMA, KALV, and TRVN Headlines

Source	Headline
	XOMA (NASDAQ:XOMA) Share Price Crosses Above 200-Day Moving Average of $20.30 americanbankingnews.com - April 25 at 3:14 AM
	Actym Therapeutics Appoints Thomas Smart as CEO prnewswire.com - April 24 at 9:00 AM
	XOMA (NASDAQ:XOMA) shareholders have earned a 16% CAGR over the last five years finance.yahoo.com - April 20 at 9:43 AM
	XOMA (NASDAQ:XOMA) Share Price Passes Above Two Hundred Day Moving Average of $19.93 americanbankingnews.com - April 17 at 2:58 AM
	XOMA Co. (NASDAQ:XOMA) Shares Sold by Stonepine Capital Management LLC marketbeat.com - April 9 at 9:43 PM
	XOMA Corporation Announces Closing of Tender Offer globenewswire.com - April 3 at 9:00 AM
	XOMA Declares Quarterly Preferred Stock Dividends globenewswire.com - March 21 at 7:30 AM
	XOMA Announces Calculation of Additional Price Per Share and Extension of Expiration Date for Tender Offer for Kinnate Biopharma Inc. globenewswire.com - March 19 at 4:05 PM
	KINNATE BIOPHARMA INVESTOR ALERT BY THE FORMER ATTORNEY GENERAL OF LOUISIANA: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Kinnate Biopharma Inc. - KNTE businesswire.com - March 13 at 11:49 AM
	XOMA Stock Earnings: XOMA Misses EPS, Misses Revenue for Q4 2023 investorplace.com - March 8 at 1:03 PM
	XOMA Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights Recent and Upcoming Events Expected to Drive Shareholder Value finance.yahoo.com - March 8 at 7:51 AM
	XOMA Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights Recent and Upcoming Events Expected to Drive Shareholder Value globenewswire.com - March 8 at 7:30 AM
	XOMA to Present at Upcoming Investor Conferences in March globenewswire.com - February 28 at 7:30 AM
	KINNATE BIOPHARMA INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Kinnate Biopharma Inc. - KNTE businesswire.com - February 19 at 11:03 AM
	Compare with Maple Leaf Green World Inc (4HV0) msn.com - February 18 at 12:30 PM
	XOMA to acquire Kinnate Biopharma thepharmaletter.com - February 17 at 10:21 AM
	XOMA Mar 2024 20.000 put finance.yahoo.com - February 17 at 10:21 AM
	XOMA Jun 2024 25.000 call finance.yahoo.com - February 17 at 10:21 AM
	Biotech Royalty Aggregator XOMA To Acquire Small Cancer-Drug Developer Kinnate Biopharma benzinga.com - February 16 at 1:37 PM
	XOMA Agrees to Acquire Kinnate Biopharma marketwatch.com - February 16 at 8:36 AM
	XOMA Enters into Agreement to Acquire Kinnate Biopharma for Between $2.3352 and $2.5879 in Cash Per Share Plus a Contingent Value Right finance.yahoo.com - February 16 at 8:36 AM
	XOMA Enters into Agreement to Acquire Kinnate Biopharma for Between $2.3352 and $2.5879 in Cash Per Share Plus a Contingent Value Right finance.yahoo.com - February 16 at 8:36 AM
	XOMA Enters into Agreement to Acquire Kinnate Biopharma for Between $2.3352 and $2.5879 in Cash Per Share Plus a Contingent Value Right globenewswire.com - February 16 at 8:00 AM
	With 37% ownership, XOMA Corporation (NASDAQ:XOMA) has piqued the interest of institutional investors finance.yahoo.com - January 20 at 2:06 PM

New MarketBeat Followers Over Time

Media Sentiment Over Time

Company Descriptions

Aptinyx

NASDAQ:APTX

Aptinyx Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of novel, proprietary, and synthetic small molecules for the treatment of brain and nervous system disorders. Its lead product candidate NYX-783, an N-methyl-D-aspartate receptors (NMDAr) modulator that is in Phase I clinical trial to treat opioid use disorder, or OUD; and in preclinical trial for the treatment of alcohol use disorder, or AUD. The company has a research collaboration agreement with Allergan plc. Aptinyx Inc. was incorporated in 2015 and is headquartered in Evanston, Illinois.

KalVista Pharmaceuticals

NASDAQ:KALV

KalVista Pharmaceuticals, Inc., a clinical stage pharmaceutical company, engages in the discovery, development, and commercialization of small molecule protease inhibitors for diseases with unmet needs in the United States. The company's product portfolio comprises small molecule plasma kallikrein inhibitors targeting hereditary angioedema (HAE) and diabetic macular edema (DME); and oral plasma kallikrein inhibitors. Its products include sebetralstat, which is initiation of the Phase 3 KONFIDENT trial as a potential oral, on-demand therapy for HAE attacks; and Factor XIIa, an oral inhibitor program which is in preclinical stage targets an enzyme in HAE. The company is headquartered in Cambridge, Massachusetts.

Lannett

NYSE:LCI

Lannett Co., Inc. engages in the development, manufacture, marketing, and distribution of generic pharmaceutical products. It offers products in different forms including capsules, tablets, liquids, powders, and sprays. The company was founded in 1942 and is headquartered in Trevose, PA.

Trevena

NASDAQ:TRVN

Trevena, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel medicines for patients affected by central nervous system disorders. Its lead product candidates include OLINVYK (Oliceridine) injection, a G protein biased mu-opioid receptor (MOR) ligand for the management of moderate-to-severe acute pain; TRV250, a G protein biased delta-opioid receptor agonist for the treatment of acute migraine; TRV734, a small molecule G protein biased ligand of the MOR for the treatment of moderate-to-severe acute and chronic pain; and TRV045, a novel S1P modulator for managing chronic pain. Trevena, Inc. was incorporated in 2007 and is based in Chesterbrook, Pennsylvania.

XOMA

NASDAQ:XOMA

XOMA Corporation operates as a biotech royalty aggregator in the United States and the Asia Pacific. It has a portfolio of economic rights to future potential milestone and royalty payments associated with partnered commercial and pre-commercial therapeutic candidates. The company also focuses on early to mid-stage clinical assets primarily in Phase 1 and 2 with commercial sales potential that are licensed to partners; and acquires milestone and royalty revenue streams on late-stage clinical or commercial assets. It has a portfolio with various assets. XOMA Corporation was incorporated in 1981 and is headquartered in Emeryville, California.

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial